Business Wire

ESI Virtual Prototyping Supports JMDA’s Red Dot Award

22.10.2020 10:00:00 EEST | Business Wire | Press release

Share

With a relationship that spans more than a decade, JMDA Design and ESI Group (Paris:ESI) worked together on the Tinyseats child car seat project which resulted in the highly acclaimed Red Dot Award: Design Concept 2020.

Multi-award winning JMDA Design has collaborated with ESI Group, a global player in virtual prototyping software and services for industrials, for many years. Their unique partnership enabled the Tinyseats child car seat project from Tinyseats Europe AB to undergo rigorous testing without the need of any physical prototypes. They were able to do this at the early stages of development to gain additional information about product performance and to help de-risk compliance challenges in a test situation. Using Virtual Prototyping by working with ESI Group, particularly for innovative, cutting-edge child restraint systems (CRS), ensures dynamic performance is optimised with controlled time and investment, from the upstream phases of the product design process.

Derrick Barker, Founder and Director at JMDA explains, “The Red Dot Award: Design Concept 2020 for the Tinyseats child car seat was a ground-breaking project aiming to achieve a very lightweight, compact and convertible car seat for children from 9 months old. Working with ESI Group enabled JMDA to gain substantial insight into the performance of the car seat early on in the design process, especially the load bearing structure, which could be fully evaluated in a virtual environment.” Derrick adds, “As our relationship goes from strength to strength with ESI Group we are backed by a team sharing our passion for innovation with the highest safety standards”.

We are really proud to be part of JMDA journey for many years now. Their commitment toward safety and comfort compelled with their undisputed design expertise make them a key player in the car seat industry. Helping industrials to commit to such outcome is truly embarked in our DNA and our strategy. This Red Do Award proves that allowing any compromise between, design, safety and performance is possible with the appropriate expertise, solutions and trust-based relationship.” declares Jonas Fredriksson, Managing Director – ESI Northern Europe

JMDA Design, a global provider for product design services with nearly 30 years’ experience in the industry, is currently designing their 105th child car seat, have. Partnering with world leading specialists, like ESI Group, is a critical part of ensuring a truly holistic approach to innovative product design.

About ESI

Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.

Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

For more information about the partnership between JMDA Design and ESI Group, please give Derrick Barker a call on +44 (0) 1386 426100 or email derrick.barker@jmda.co.uk.

- ENDS -

Notes to Editor

- JMDA Design specialise in the design and development of a diverse range of products including child car seats, stair lifts, showers, smoke alarms and highchairs.
- JMDA Design have two offices one in Pershore, Worcestershire and one in Shanghai, China.
- They support clients across the world with testing, manufacturing and distribution of the products they design.
- Awards for innovation and international activity include:

2020 – Winners of Red Dot Award: Design Concept 2020
2019 - Winners of The Queen’s Awards for Enterprise: International Trade 2019
2019 – Winners of a German Design Award 2020
2018 – International Design Award Winners
2017 - Highly Commended ‘Exporter of the Year’ - Hereford and Worcestershire Chamber of Commerce Awards
2016 – Winners of Red Dot Award: Design Concept 2016
2014 – Winner of the Progressive Preschool Innovation Award (Flippa Folding Dining Booster)
2012 – Finalist of the Hereford and Worcestershire Chamber of Commerce International Business Award
2010 – Winner of the International Business of the Year Award
2009 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Chamber of Commerce Small Business of the Year Award

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ESI – Press contact
Florence Barré
press@esi-group.com

SHAN – Press Relations
Esigroup@shan.fr

For more information contact:
Christina Darling – Marketing & PR Manager

JMDA
Units 1 Common Barns
Hill Furze, Nr Pershore
Worcestershire
WR10 2NU
Phone: +44 (0) 1386 426100
Mobile: +44 (0) 7719 430267
Fax: +44 (0) 01386 426048

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye